Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. - Halbert CL; Miller AD; McNamara S; Emerson J; Gibson RL; Ramsey B; Aitken ML (Human gene therapy, 2006)